Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Pierre-Olivier Tremblay"'
Autor:
Nassim Djebli, Pierre-Olivier Tremblay, Vincent Buchheit, Mario González-Sales, Guillaume Bonnefois, Georgina Meneses-Lorente, Francois Mercier, Nicolas Frey
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:997-1007
Entrectinib (ROZLYTREK®) is a CNS-active, potent, and selective inhibitor of ROS1, TRK A/B/C, and ALK kinase activity. It was recently approved for the treatment of ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors.
Modeling Testosterone Circadian Rhythm in Hypogonadal Males: Effect of Age and Circannual Variations
Autor:
Olivier Barrière, Mario Tanguay, Julie Desrochers, Fahima Nekka, Pierre-Olivier Tremblay, Mario González-Sales
Publikováno v:
The AAPS Journal
The objective of this study was to characterize the baseline circadian rhythm of testosterone levels in hypogonadal men. A total of 859 baseline profiles of testosterone from hypogonadal men were included in this analysis. The circadian rhythm of the
Autor:
Raphaël, Vlavonou, Marc M, Perreault, Olivier, Barrière, Eric, Shink, Pierre-Olivier, Tremblay, Richard, Larouche, Vincent, Pichette, Mario, Tanguay
Publikováno v:
Journal of clinical pharmacology. 54(5)
The pharmacokinetics of baclofen is well delineated in subjects with normal kidney function (KF); however, pharmacokinetics data in patients with chronic kidney disease (CKD) are not and dosage recommendations remain empirical. The effects of CKD on